Parvovirus B19 infection and pregnancy;Infection à parvovirus B19 et grossesse

Presse Medicale

Volumn 44, Issue 6, 2015, Pages 647-653

  Subtil, Damien ^a   Garabedian, Charles ^a   Chauvet, Agathe ^a  

^a UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABORTION; ADAPTIVE IMMUNITY; AGE DISTRIBUTION; ANEMIA; COMMUNICABLE DISEASE; DISEASE SEVERITY; ERYTHEMA INFECTIOSUM; FEMALE; FETUS HYDROPS; FETUS MORTALITY; HUMAN; HUMAN PARVOVIRUS B19; NERVOUS SYSTEM INJURY; PREGNANCY; PREGNANT WOMAN; PREVALENCE; SHORT SURVEY; SPRING; STIGMA; VIRUS TRANSMISSION; FETAL DISEASES; PARVOVIRIDAE INFECTIONS; PATHOPHYSIOLOGY; PREGNANCY COMPLICATIONS, INFECTIOUS; TRANSMISSION; VERTICAL TRANSMISSION; VIROLOGY;

FEMALE; FETAL DISEASES; HUMANS; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PARVOVIRIDAE INFECTIONS; PARVOVIRUS B19, HUMAN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 84956592796     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2015.04.013     Document Type: Short Survey

References (47)

1. Enders M., et al. Fetal morbidity and mortality after acute human parvovirus B19 infection in pregnancy: prospective evaluation of 1018 cases. Prenat Diagn 2004, 24:513-518.
2. Rodis J.F. Parvovirus infection. Clin Obstet Gynecol 1999, 42(1):7-20. quiz 174-5.
3. Lefrere J.J. Safety of blood products and B19 parvovirus B19. Transfus Clin Biol 2006, 13(4):235-241.
4. Cohen B.J. The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol 1988, 25(2):151-153.
5. Valeur-Jensen A. Risk factors for parvovirus B19 infection in pregnancy. JAMA 1999, 281(12):1099-1105.
6. Gratacos E. The incidence of human parvovirus B19 infection during pregnancy and its impact on perinatal outcome. J Infect Dis 1995, 171(5):1360-1363.
7. Kerr J. An outbreak of parvovirus B19 infection; a study of clinical manifestations and the incidence of fetal loss. Ir J Med Sci 1994, 163(2):65-67.
8. Harger J.H. Prospective evaluation of 618 pregnant women exposed to parvovirus B19: risks and symptoms. Obstet Gynecol 1998, 91(3):413-420.
9. Woernle C. Human parvovirus B19 infection during pregnancy. J Infect Dis 1987, 156(1):17-20.
10. Gay N.J. Age specific antibody prevalence to parvovirus B19: how many women are infected in pregnancy?. Commun Dis Rep CDR Rev 1994, 4(9):R104-R107.
11. Morel O. Parvovirus B19 in pregnancy: literature review. Gynecol Obstet Fertil 2007, 35(11):1095-1104.
12. Chisaka H. Clinical manifestations and outcomes of parvovirus B19 infection during pregnancy in Japan. Tohoku J Exp Med 2006, 209(4):277-283.
13. Yaegashi N., et al. The incidence of, and factors leading to, parvovirus B19-related hydrops fetalis following maternal infection; report of 10 cases and meta-analysis. J Infect 1998, 37(1):28-35.
14. Jensen I. An epidemic of parvovirus B19 in a population of 3596 pregnant women: a study of sociodemographic and medical risk factors. BJOG 2000, 107(5):637-643.
15. Cartter M. Occupational risk factors for infection with parvovirus B19 among pregnant women. J Infect Dis 1991, 163(2):282-285.
16. Bell L. Human parvovirus B19 infection among hospital staffmembers after contact with infected patients. N Engl J Med 1989, 321(8):485-491.
17. Miller E., et al. Immediate and long-term outcome of human parvovirus B19 infection in pregnancy. Br J Obstet Gynaecol 1998, 105(2):174-178.
18. Young N. Parvovirus infection and its treatment. Clin Exp Immunol 1996, 104(Suppl. 1):26-30.
19. Broliden K. Clinical aspects of parvovirus B19 infection. J Intern Med 2006, 260(4):285-304.
20. Skjoldebrand-Sparre L. Parvovirus B19 infection: association with third-trimester intrauterine fetal death. BJOG 2000, 107(4):476-480.
21. Jordan J. DeLoia, Globoside expression within the human placenta. Placenta 1999, 20(1):103-108.
22. Rodis J. Long-term outcome of children following maternal human parvovirus B19 infection. Obstet Gynecol 1998, 91(1):125-128.
23. Guidozzi F. Human B19 parvovirus infection in an obstetric population. A prospective study determining fetal outcome. J Reprod Med 1994, 39(1):36-38.
24. Rodis J. Management and outcomes of pregnancies complicated by human B19 parvovirus infection: a prospective study. Am J Obstet Gynecol 1990, 163(4 Pt 1):1168-1171.
25. Sheikh A. Long-term outcome in fetal hydrops from parvovirus B19 infection. Am J Obstet Gynecol 1992, 167(2):337-341.
26. Morey A. Parvovirus B19 infection and transient fetal hydrops. Lancet 1991, 337(8739):496.
27. Naides S. Antenatal diagnosis and palliative treatment of nonimmune hydrops fetalis secondary to fetal parvovirus B19 infection. Prenat Diagn 1989, 9(2):105-114.
28. Levy R. Infection by parvovirus B 19 during pregnancy: a review. Obstet Gynecol Surv 1997, 52(4):254-259.
29. de Krijger R. Detection of parvovirus B19 infection in first and second trimester fetal loss. Pediatr Pathol Lab Med 1998, 18(1):23-34.
30. Wilcox A. Incidence of early loss of pregnancy. N Engl J Med 1988, 319(4):189-194.
31. Markenson G. Parvovirus B19 infections in pregnancy. Semin Perinatol 1998, 22(4):309-317.
32. Bellini C., et al. Etiology of nonimmune hydrops fetalis: a systematic review. Am J Med Genet A 2009, 149A(5):844-851.
33. von Kaisenberg C. A case of fetal parvovirus B19 myocarditis, terminal cardiac heart failure, and perinatal heart transplantation. Fetal Diagn Ther 2001, 16(6):427-432.
34. Katz V. An association between fetal parvovirus B19 infection and fetal anomalies: a report of two cases. Am J Perinatol 1996, 13(1):43-45.
35. Carrington D., et al. Maternal serum alpha-fetoprotein - a marker of fetal aplastic crisis during intrauterine human parvovirus infection. Lancet 1987, 1(8530):433-435.
36. Ergaz Z. Parvovirus B19 in pregnancy. Reprod Toxicol 2006, 21(4):421-435.
37. Enders M. Current epidemiological aspects of human parvovirus B19 infection during pregnancy and childhood in the western part of Germany. Epidemiol Infect 2006, 1-7.
38. Fairley C. Observational study of effect of intrauterine transfusions on outcome of fetal hydrops after parvovirus B19 infection. Lancet 1995, 346(8986):1335-1337.
39. Garabedian C. Is intrauterine exchange transfusion a safe procedure for management of fetal anemia. J Obstet Gynecol Reprod Biol 2014, 179:83-87.
40. Rodis J. Management of parvovirus infection in pregnancy and outcomes of hydrops: a survey of members of the Society of Perinatal Obstetricians. Am J Obstet Gynecol 1998, 179(4):985-988.
41. von Kaisenberg C. Fetal parvovirus B19 infection. Ultrasound Obstet Gynecol 2001, 18(3):280-288.
42. Chauvet A. Ultrasound diagnosis management and prognosis in a consecutive series of 27 cases of fetal hydrops following maternal parvovirus B19 infection. Fetal diagnosis Ther 2011, 30(1):41-47.
43. Saint-Martin J. Myocarditis caused by parvovirus. J Pediatr 1990, 116(6):1007-1008.
44. Yoto Y. Transient disturbance of consciousness and hepatic dysfunction associated with human parvovirus B19 infection. Lancet 1994, 344(8922):624-625.
45. Brown K. Congenital anaemia after transplacental B19 parvovirus infection. Lancet 1994, 343(8902):895-896.
46. Nagel H. Long-term outcome after fetal transfusion for hydrops associated with parvovirus B19 infection. Obstet Gynecol 2007, 109(1):42-47.
47. Shelly D. Parvovirus B19 VLP vaccine manufacturing. Gen Eng Biotechnol News 2009, 29(16). consulté le 11/05/2015. http://genengnews.com/gen-articles/parvovirus-b19-vlp-vaccine-manufacturing/3042/.